Mammography Systems Market Size & Share 2026-2035

Mammography Systems Market Size

The global mammography systems market reaching USD 3.6 billion in 2025. It is projected to rise from USD 3.9 billion in 2026 to USD 7.5 billion by 2035, at a 7.5% CAGR during 2026-2035.

Mammography systems encompass analog screen-film equipment, full field digital mammography (FFDM), breast tomosynthesis systems, and newer contrast-enhanced mammography (CEM) configurations. Demand rests on a widening need for both population screening and diagnostic workup. IARC estimated 2.3 million new breast cancer cases and 670,000 deaths worldwide in 2022, and projects annual incidence to reach 3.2 million cases by 2050 if current trends persist. ^[1] Breast cancer was also identified as the most commonly diagnosed cancer globally among women in 2022.

The demand base is geographically broad but commercially uneven. China, the United States, and India recorded the largest absolute breast cancer case counts in 2022, placing the largest future screening-volume requirements across markets with materially different reimbursement capacity and imaging infrastructure. ^{[2]World Cancer Research Fund, wcrf.org} In mature screening markets, system sales increasingly depend on replacement cycles and premium upgrades from 2D digital systems to DBT, CEM, and AI-enabled workflows. In lower-resource settings, the commercial opportunity remains more closely tied to first digital installations, service access, and the ability to operate image-management infrastructure reliably.

The top five suppliers - Hologic, GE HealthCare, Siemens Healthineers, Philips, and Fujifilm - collectively account for 42.5% of global market revenue. This concentration is most visible in premium DBT and CEM procurement, where regulatory clearances, clinical workflow integration, installed-base service coverage, and software compatibility can matter as much as detector performance.

Technology is changing the economics of replacement rather than simply adding a higher-priced modality. DBT improves lesion conspicuity and CEM extends functional imaging capability, but both introduce workflow, reimbursement, and training considerations. Suppliers able to pair hardware with reading support, contrast-injection workflows, and service infrastructure are better positioned to capture replacement demand than suppliers competing on gantry specifications alone. The 42.5% share held by the five largest vendors therefore understates the importance of installed-base control in high-value procurement decisions.

Key Drivers

Breast cancer incidence provides the market's long-term volume foundation. IARC projects a 38% increase in annual global breast cancer cases between 2022 and 2050, while deaths are projected to rise by 68% to about 1.1 million annually. For imaging providers, the implication is not a uniform increase in equipment demand, but a sustained need for screening capacity in high-incidence markets and diagnostic access in regions where delayed presentation remains common.

Increasing incidence of breast cancer across the globe

Absolute disease burden is concentrated in markets that are also central to future procurement. China recorded 357,161 new breast cancer cases in 2022, followed by the United States with 274,375 and India with 192,020. In North America and Western Europe, this burden reinforces replacement demand within established screening networks. In China and India, it strengthens the case for expanding digital mammography access beyond tertiary urban hospitals, although capital availability and radiologist capacity remain decisive constraints.

Growing awareness about breast cancer screening and early detection

Guideline changes can quickly translate epidemiological demand into reimbursable imaging volume. The USPSTF recommended biennial mammography screening for women aged 40-74 in April 2024, extending the routine screening recommendation to women in their forties. ^{[3]U.S. Preventive Services Task Force, uspreventiveservicestaskforce.org} The recommendation is reinforced by the evidence base published alongside it. In the United States, 76.5% of women aged 50-74 reported receiving a mammogram within the preceding two years, indicating that future growth will depend increasingly on reaching younger eligible patients, underserved groups, and women outside established screening patterns.

Europe's policy framework creates a different procurement mechanism. The EU's cancer screening agenda seeks to offer breast cancer screening to 90% of the eligible population by 2025. The European Commission has continued to position screening quality, coverage, and care pathways as linked components of breast cancer control. The implementation gap across member states leaves demand concentrated not only in new equipment purchases, but also in quality assurance, workflow modernization, and replacement of older digital fleets.

Rising government funding for breast cancer screening tests in developed countries

Public programs turn screening policy into recurring equipment utilization. The U.S. National Breast and Cervical Cancer Early Detection Program provided breast cancer screening and diagnostic services to 305,992 women in 2024, identifying 2,062 invasive breast cancers and 702 premalignant lesions. Proposed U.S. legislation has included authorization levels intended to support the program through fiscal year 2028. Where such programs are funded, demand is less dependent on discretionary patient spending and more closely tied to the ability of participating sites to maintain compliant, high-throughput imaging capacity.

The United Kingdom provides a near-term test case for AI-supported procurement. In February 2025, the UK government launched the £11 million EDITH trial across 30 breast screening sites, with approximately 700,000 women expected to participate. The study is designed to examine whether AI can support mammography reading at population scale. Its commercial importance extends beyond software: successful AI-supported workflows could alter the specifications sought for replacement mammography systems, particularly where digital image integration and reading efficiency are evaluated together.

Technological advancements

DBT is shifting procurement toward platforms that improve detection while avoiding an unsustainable increase in recall or reading workload. A systematic review and meta-analysis found higher sensitivity for DBT alone and DBT combined with digital mammography than for digital mammography alone, with reported sensitivity of 88% for DBT compared with 79% for digital mammography. Community-practice evidence also found a 28.6% higher overall cancer detection rate and a 16.1% lower recall rate with 3D DBT than with 2D digital mammography. A broader meta-analysis confirms that DBT-based screening can improve cancer detection, including invasive cancer detection, relative to digital mammography alone.

AI support addresses the operational bottleneck created by higher image volumes. A nationwide German implementation study covering 463,094 women found a 17.6% higher cancer detection rate in the AI-supported reading group than in standard reading, with non-inferior recall. ^{[4]Leibig C. et al., nature.com} A systematic review found that AI triage and decision-referral models can reduce radiologist reading volumes by 40-90% while maintaining non-inferior cancer detection in the reviewed configurations. The MASAI study further reported higher sensitivity and a 12% reduction in interval cancer rate for AI-supported screening compared with standard double reading. These outcomes create a practical procurement rationale for AI-compatible mammography systems where radiologist capacity is a binding constraint.

CEM provides a distinct upgrade route for diagnostic breast imaging. The modality can offer functional lesion information using dual-energy mammography and iodinated contrast, creating an alternative for selected diagnostic indications traditionally associated with MRI. Its adoption is moderated by contrast-management requirements, reimbursement gaps, and incomplete standardization of clinical indications. In an EUSOBI survey of 434 radiologists, 50% of respondents reported using CEM, most frequently for patients with MRI contraindications and for preoperative staging. A 2024 clinical validation study also reported favorable diagnostic accuracy and efficiency for CEM compared with standard mammography and DBT in the evaluated setting.

Key Restraints

High capital investment

The move from screen-film to FFDM, and from FFDM to DBT or CEM-ready configurations, increases the capital and operating requirements placed on providers. The purchase decision extends beyond the imaging unit to PACS connectivity, image storage, maintenance coverage, contrast-management processes, quality compliance, and staffing. This broad cost base makes acquisition economics particularly difficult for public hospitals and community facilities in lower-income settings.

The cost-effectiveness of DBT is sensitive to reimbursement, recall reduction, and the price premium over conventional digital mammography. In systems that bundle DBT reimbursement with standard FFDM payments, providers may capture the clinical benefit without an equivalent revenue increase. Consequently, adoption can lag clinical evidence in publicly financed markets, particularly where existing FFDM fleets have remaining useful life.

False-negative results and diagnostic limitation

Mammography remains the foundation of population screening, but it does not eliminate missed cancers. The USPSTF evidence summary reported false-negative rates of 1.0-1.5 per 1,000 women per screening round in a large dataset of digital mammography examinations. Dense breast tissue and patient age can complicate image interpretation, while high-volume environments heighten the importance of consistent reading performance.

This limitation creates both an upgrade opportunity and a substitution risk. DBT, CEM, AI-supported reading, ultrasound, and MRI can supplement conventional mammography for selected pathways, but they also make a basic 2D system less defensible for facilities serving complex diagnostic populations. The commercial consequence is a segmented market: basic FFDM remains essential for broad screening access, while premium systems gain relevance where providers must demonstrate improved detection, lower recalls, or better management of dense-breast cases.

False-negative risk does not diminish the role of mammography; it raises the standard for platform selection. Facilities serving dense-breast populations or high-volume diagnostic pathways have stronger incentives to adopt DBT, CEM, and AI-enabled reading support, whereas programs focused on geographic access may prioritize durable FFDM capacity and mobile deployment. Suppliers that price advanced capability as a modular progression rather than an all-or-nothing system replacement are better aligned with this split in buyer economics.

Mammography Systems Market Segment Analysis

By Product

Full Field Digital Mammography Systems

FFDM systems held 65.4% of market revenue in 2025 and are projected to reach USD 4.7 billion by 2035 at a 7.0% CAGR. Their leadership reflects the scale of the installed base across North America, Europe, Japan, and Australia, as well as the continuing replacement of screen-film systems in middle-income countries. FFDM remains the essential platform for organized screening because it combines throughput, digital archiving, and interoperability with a lower acquisition threshold than DBT or CEM configurations.

The segment's growth rate below the overall market does not indicate diminishing clinical relevance. Instead, it reflects a maturing base in advanced markets, where incremental spending is migrating toward tomosynthesis, AI integration, and contrast capability. The competitive focus within FFDM is consequently shifting from core image acquisition to upgradeability, service coverage, connectivity, and the ability to support a future transition to advanced modalities.

Breast Tomosynthesis Systems

Breast Tomosynthesis Systems are projected to reach USD 2.6 billion by 2035 at an 8.7% CAGR, the fastest rate among product categories. DBT reduces tissue-overlap limitations by reconstructing multiple low-dose projections into a three-dimensional image set. Its higher value proposition is strongest in markets where screening providers can monetize better detection performance, lower recalls, or increased diagnostic confidence.

Evidence from prospective studies supports this clinical differentiation. A 2024 meta-analysis found DBT sensitivity of 86% compared with 80% for digital mammography, with comparable specificity in the included studies. ^[5] Yet the purchase decision is not based on clinical performance alone. DBT produces more image data and can increase reading demand unless paired with synthesized 2D imaging, automated workflow tools, or AI triage. This makes DBT procurement most attractive for providers that can translate performance improvements into sustainable radiologist productivity.

Analog Systems

Analog Systems are projected to reach USD 170.1 million by 2035 at a 4.0% CAGR. Their residual role is concentrated in settings where unreliable power, constrained PACS availability, limited IT support, or scarce maintenance capacity make full digital deployment difficult. The segment therefore represents an access-driven market rather than a technology-growth market.

Analog demand should not be interpreted as a stable long-term substitute for digital systems. It often reflects a transitional stage in infrastructure development. The IAEA's Rays of Hope initiative reported mammography unit delivery to six member states in Latin America in 2024, illustrating how external support can expand access where domestic procurement budgets are insufficient. ^{[6]International Atomic Energy Agency, iaea.org}

By Technology

Screen Film

Screen Film is projected to reach USD 106.3 million by 2035 at a 6.9% CAGR. Revenue is sustained by remaining installed systems, deferred replacement decisions, and isolated first-installation demand in settings without dependable digital infrastructure. Its market role is increasingly defined by operational feasibility rather than clinical preference.

2D Mammography

2D Mammography is projected to reach USD 3.8 billion by 2035 at a 7.2% CAGR. It remains the volume foundation of organized screening because FFDM is widely deployable across hospitals, mobile services, and outpatient imaging facilities. The April 2024 U.S. screening recommendation expands the eligible population for routine biennial screening and supports continued examination-volume growth for 2D and DBT-capable fleets alike.

3D Mammography

3D Mammography is projected to reach USD 2.9 billion by 2035 at a 7.6% CAGR. Growth is supported by replacement of mature FFDM systems in North America and Western Europe, alongside adoption in tertiary centers across Asia Pacific. The technology's premium is easier to defend where providers can use AI-supported reading to manage the larger image set and where synthesized 2D imaging reduces concerns about dose from combined 2D and DBT acquisition.

Contrast-Enhanced Mammography

CEM is projected to reach USD 399.5 million by 2035 at an 8.2% CAGR, making it the fastest-growing technology segment. Its value lies in extending a mammography room into a diagnostic pathway that can provide contrast-enhancement information for selected cases without the full cost and scheduling burden of breast MRI. Adoption is likely to concentrate initially in high-volume breast centers, diagnostic clinics, and hospitals with established contrast-management protocols.

The modality's near-term ceiling is defined by workflow rather than image quality alone. Providers must manage contrast injection, adverse-event protocols, reimbursement uncertainty, and clinical training. Those requirements favor suppliers that can coordinate the gantry, injection workflow, and clinical implementation instead of treating CEM as a feature added to a standard mammography platform.

Other Technologies

Other Technologies include photon-counting mammography and specialized imaging configurations. These systems remain a smaller commercial category, but they demonstrate the direction of premium imaging development: lower-dose acquisition, spectral capability, and more detailed lesion characterization. Their commercial significance is currently greater as a technology pathway than as a near-term volume driver.

By End Use

Hospitals

Hospitals are projected to reach USD 4.5 billion by 2035 at a 7.5% CAGR. They remain the principal purchasers for organized screening programs, diagnostic workup, biopsy integration, and high-acuity breast imaging. Their larger capital budgets and multidisciplinary workflows make them the most likely early adopters of DBT, CEM, and AI-supported reading platforms.

Hospital demand is also more sensitive to whole-workflow economics than to purchase price alone. A system that reduces recalls, improves patient throughput, or integrates with enterprise imaging can justify a premium more easily in a large hospital network than in a stand-alone site. This makes the hospital segment central to early technology diffusion, even when screening delivery later shifts into outpatient settings.

Ambulatory Surgical Centers

Ambulatory Surgical Centers are projected to reach USD 2.0 billion by 2035 at an 8.0% CAGR. Dedicated breast imaging centers and outpatient women's health facilities benefit from shorter patient pathways, specialized scheduling, and the ability to configure workflows around high-volume screening. Their growth favors systems with efficient positioning, compact workflows, AI-supported triage, and cloud-enabled image management.

This segment is commercially important because it can accelerate the replacement cycle. Independent or network-owned centers have fewer competing imaging priorities than hospital radiology departments and can differentiate on patient experience, appointment availability, and same-day diagnostic follow-up. Vendors that offer scalable configurations and predictable service economics are better positioned to participate in this shift.

Others

Others are projected to reach USD 932.1 million by 2035 at a 6.7% CAGR and include research institutions, specialty clinics, and mobile mammography programs. Mobile units are particularly important in extending services to rural, uninsured, and geographically dispersed populations. Their value is not simply the unit sale; they can create the first structured screening pathway in areas that later support fixed-site equipment deployment.

The end-use mix reinforces this separation. Hospitals are likely to remain the first setting for advanced modalities because they can absorb clinical integration and capital costs, while outpatient centers can accelerate adoption once workflows become more standardized. Procurement strategies should therefore distinguish between a fleet-renewal sale, a diagnostic-capability upgrade, and an access-expansion deployment. Treating each as a single equipment category obscures the different commercial and service requirements attached to the same mammography platform.

Mammography Systems Market Regional Analysis

North America

North America held 34.8% of global mammography systems market revenue in 2025, equivalent to USD 1.15 billion, and is projected to expand at a 7.1% CAGR. The United States generated USD 924.5 million in 2022, USD 993.5 million in 2023, USD 1.07 billion in 2024, and USD 1.15 billion in 2025. Mature digital penetration makes the region a technology replacement market, with spending increasingly directed toward DBT, AI-enabled reading, CEM capability, and patient-throughput improvement.

United States

The USPSTF recommendation for biennial screening from age 40 increases the potential screening population and strengthens the policy case for capacity expansion. U.S. providers are also more likely than those in many public systems to link capital decisions to reimbursement, reading productivity, and workflow differentiation. The resulting demand favors DBT-capable platforms, AI integration, and systems that can support same-day diagnostic pathways.

Canada

Canada's provincial screening programs support recurring replacement demand through publicly organized procurement. The market is more likely to adopt advanced capability through tertiary and regional breast centers than through fragmented private purchasing. Canada was also identified as a target geography in the Hologic-Bayer collaboration to expand CEM adoption.

Europe

Europe generated USD 1.0 billion in market revenue in 2025. Organized screening infrastructure, national quality standards, and EU-level coverage ambitions make the region a major equipment market, but procurement varies substantially by country. Germany, the United Kingdom, France, Spain, Italy, and the Netherlands all operate established screening pathways, although DBT penetration and financing differ across these markets.

Germany

Germany's national screening system provides a structured setting for AI adoption. The German real-world study covering 12 sites demonstrated improved cancer detection with AI-supported reading, making AI compatibility increasingly relevant to future equipment decisions. The commercial opportunity is therefore concentrated in replacement platforms that support advanced workflow integration rather than in basic conversion from analog equipment.

United Kingdom

The NHS screening program provides a large, centralized buyer environment. The EDITH trial's scale and government funding create a potential route for AI-supported mammography to influence future NHS technical specifications. A positive result would make reading workflow and vendor interoperability more important in procurement than stand-alone imaging hardware features.

France, Spain, Italy, and the Netherlands

France, Spain, Italy, and the Netherlands maintain organized national or regional screening programs. Their demand is shaped by the pace at which current FFDM infrastructure is replaced with DBT-capable systems and by how national programs interpret European screening guidance. Coverage differences across Europe make infrastructure expansion relevant alongside advanced-modalities replacement.

Asia Pacific

Asia Pacific generated USD 916.7 million in 2025 and represents the most significant volume-growth geography. China, Japan, India, Australia, and South Korea combine high and growing disease burden with highly varied levels of screening maturity, domestic manufacturing capability, and public funding.

China

China's 357,161 new breast cancer cases in 2022 make it the largest absolute case-count market globally. Demand is supported by hospital infrastructure investment and a growing domestic supplier base, but procurement remains price-sensitive outside top-tier urban institutions. Local OEM competition can limit pricing for entry-level digital systems while creating a separate opportunity for international suppliers at the premium DBT and workflow-integration end of the market.

Japan

Japan has a mature screening infrastructure and high penetration of advanced imaging systems. Demand is more replacement-led than access-led, with providers evaluating advanced technology through clinical quality, dose management, and workflow efficiency rather than basic digitization.

India

India recorded 192,020 new breast cancer cases in 2022. Its opportunity is defined by the need to build access across a large population with pronounced urban-rural disparities. Digital first installations, mobile mammography, and lower-cost service models are likely to remain more commercially relevant than high-end DBT expansion outside major cities.

Australia and South Korea

Australia's BreastScreen program and South Korea's National Cancer Screening Program provide stable screening demand in technologically advanced markets. South Korea's national program is particularly relevant to AI adoption because screening workflows already operate at substantial scale, allowing performance evidence to influence platform selection.

Latin America

Latin America represented approximately 8.6% of global revenue in 2025. Brazil, Mexico, and Argentina are the largest country markets, while screening coverage remains uneven across public and private systems. A narrative review of studies from Mexico, Brazil, Peru, and Chile reported mammography coverage ranging from approximately 20% to 60%, with lower uptake among rural, indigenous, and uninsured populations. ^[7]

Brazil's 94,728 new breast cancer cases in 2022 highlight the scale of unmet diagnostic need. Brazil and Mexico remain the most important commercial markets for OEM distribution, while Argentina's partial organized screening structure and regional cancer-control initiatives create a more fragmented procurement environment. The region's first digital installations and mobile programs can expand the long-term installed base, but affordability, maintenance capability, and public financing continue to govern adoption speed.

Middle East & Africa

MEA represented approximately 3% of global mammography systems market revenue in 2025. Saudi Arabia, the UAE, and South Africa illustrate the region's uneven demand structure: Gulf markets can procure premium FFDM and DBT systems for expanding health networks, while much of Sub-Saharan Africa faces basic access constraints.

WHO reported that the private sector holds 54% of functional mammography equipment across the African region, with device availability ranging from zero to 10 units per 200,000 inhabitants across countries. ^{[8]World Health Organization, who.int} The IHE's 2024 assessment of breast cancer care in MEA also identified limited public-sector mammography access and substantial variation in diagnostic infrastructure. South Africa is the region's most developed commercial market, but public-sector shortages preserve a sharp divide between private imaging capacity and broad population access. Saudi Arabia and the UAE offer a different opportunity, where healthcare investment can support premium equipment procurement but program formalization remains important for creating sustained examination volumes.

This divergence means that global growth cannot be served through a uniform product strategy. Premium-platform suppliers need local clinical support, interoperability, and reimbursement alignment in mature markets. Suppliers targeting access-constrained regions need financing, maintenance capacity, training, and digital infrastructure support. The ability to pair equipment with a credible deployment model will increasingly determine whether epidemiological need becomes installed-base growth.

Mammography Systems Market Share & Competitive Landscape

Hologic, GE HealthCare, Siemens Healthineers, Philips, and Fujifilm collectively account for 42.5% of global market revenue. Their advantage is rooted in breadth of installed base, regulatory resources, service networks, and the ability to integrate mammography into a broader imaging or breast-health workflow. The remaining market includes regional OEMs, specialized breast-imaging suppliers, and Chinese manufacturers competing more aggressively in cost-sensitive procurement.

Hologic

Hologic's mammography strategy is centered on its 3Dimensions and Selenia Dimensions platforms, DBT adoption, AI-enabled breast imaging, and expansion into adjacent breast-health services. Its April 2024 agreement to acquire Endomagnetics for approximately USD 310 million extended its portfolio into breast surgical localization and lymphatic tracing. ^[9] The transaction adds downstream clinical capability to a vendor relationship that often begins with screening and diagnostic mammography.

Hologic also partnered with Bayer in September 2023 to expand CEM adoption across Canada, Europe, and Asia Pacific. By combining mammography equipment with contrast-injection systems and training, the collaboration addresses a practical adoption barrier that hardware-only suppliers cannot resolve independently.

GE HealthCare

GE HealthCare competes through the Senographe portfolio, particularly the Senographe Pristina platform. Its November 2024 collaboration with RadNet's DeepHealth targets integration of SmartMammo AI workflow tools with Pristina. The strategic importance lies in connecting acquisition, image management, lesion detection, and worklist prioritization, rather than positioning AI as a separate add-on.

GE HealthCare introduced Pristina Via at RSNA 2024 with an emphasis on technologist workflow and patient-centered breast care. ^[10] This approach is relevant to outpatient and high-volume screening centers, where positioning efficiency and throughput can influence purchase decisions as directly as image quality.

Siemens Healthineers

Siemens Healthineers re-entered premium mammography competition with MAMMOMAT B.brilliant. The system received FDA 510(k) clearance in April 2024 for 2D imaging, CEM capability, and biopsy applications. Its PlatinumTomo 3D capability later received FDA approval in September 2024.

The platform's wide-angle tomosynthesis, CEM capability, and biopsy integration position it as a consolidated premium solution for facilities replacing multiple imaging workflows. Siemens' product architecture is particularly relevant where hospitals want to combine DBT and CEM capability without managing separate hardware investments.

Philips

Philips maintains a breast-imaging presence through MicroDose SI digital mammography and breast-imaging informatics. Its competitive relevance is strongest where providers value vendor-neutral reading environments, integration across mammography and adjunct modalities, and enterprise imaging workflow rather than a stand-alone mammography system purchase.

Fujifilm

Fujifilm competes through the ASPIRE Cristalle and AMULET product families. The company introduced AMULET SOPHINITY at ECR 2024, featuring direct-conversion detector technology, dual-angle tomosynthesis, AI-supported positioning, and CEM capability. Its strategy emphasizes image-resolution differentiation and workflow automation, positioning the platform for premium diagnostic and screening environments.

Other Companies

Analogic, Canon Medical, Carestream Health, Delphinus Medical Technologies, IMS Giotto, Konica Minolta, Neusoft Medical Systems, NP JSC Amico, Planmed, and United Imaging Healthcare comprise the remaining approved company scope.

Analogic participates in specialized breast-imaging and ultrasound adjacencies. Canon Medical and Carestream Health address digital mammography, radiography, and image-management requirements, with relevance in markets transitioning from film-based workflows. Delphinus Medical Technologies participates in supplemental breast imaging through automated breast ultrasound, while IMS Giotto and Planmed maintain specialized European mammography and DBT positions. Konica Minolta, Neusoft Medical Systems, and NP JSC Amico contribute regional digital mammography and imaging-system offerings.

United Imaging Healthcare is an increasingly significant Chinese competitor. Its uMammo portfolio includes FFDM and low-dose DBT systems with detector, dose-control, and positioning technologies intended to support global market expansion. The company reported 2024 revenue of CNY 10.30 billion and R&D investment of CNY 2.26 billion, up 17.84% year over year. Its scale and investment profile strengthen its ability to compete in domestic Chinese procurement and selected international markets where price, local support, and technology capability must be balanced.

Recent Industry Developments

November 2024 - GE HealthCare unveils Pristina Via at RSNA 2024

GE HealthCare introduced Pristina Via at RSNA 2024 as a mammography platform focused on technologist workflow, patient-centered breast care, and scalable system architecture.

February 2025 - UK government launches £11 million EDITH AI mammography trial

The UK government launched the EDITH trial in February 2025, committing £11 million to evaluate AI-supported mammography reading across 30 breast screening sites and approximately 700,000 women.